AssetMark Inc
DNLI icon

AssetMark Inc’s Denali Therapeutics DNLI Stock Holding History

AssetMark Inc’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Buy
5,216
+17
+0.3% +$349 ﹤0.01% 1547
2026
Q1 		$99.8K Buy
5,199
+12
+0.2% +$239 ﹤0.01% 1539
2025
Q4 		$85.6K Buy
5,187
+1,250
+32% +$21.1K ﹤0.01% 1548
2025
Q3 		$57.2K Buy
3,937
+317
+9% +$4.55K ﹤0.01% 1590
2025
Q2 		$50.6K Buy
3,620
+435
+14% +$6.12K ﹤0.01% 1562
2025
Q1 		$43.3K Sell
3,185
-494
-13% -$9.46K ﹤0.01% 1476
2024
Q4 		$75K Sell
3,679
-129
-3% -$3.3K ﹤0.01% 1307
2024
Q3 		$111K Buy
3,808
+580
+18% +$14.4K ﹤0.01% 1133
2024
Q2 		$75K Sell
3,228
-86
-3% -$1.65K ﹤0.01% 1159
2024
Q1 		$68K Sell
3,314
-236
-7% -$4.43K ﹤0.01% 1111
2023
Q4 		$76.2K Buy
3,550
+1,402
+65% +$27.8K ﹤0.01% 1078
2023
Q3 		$44.3K Buy
2,148
+707
+49% +$17.9K ﹤0.01% 1118
2023
Q2 		$42.5K Buy
1,441
+669
+87% +$18.8K ﹤0.01% 1118
2023
Q1 		$17.8K Buy
772
+198
+34% +$5.45K ﹤0.01% 1200
2022
Q4 		$16K Buy
574
+136
+31% +$4.05K ﹤0.01% 1242
2022
Q3 		$13K Buy
+438
New +$14.2K ﹤0.01% 1196

Other funds holding DNLI

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

AssetMark Inc's DNLI Position: Q2 2026 in Review

AssetMark Inc increased its Denali Therapeutics (DNLI) stake by 0.33% in Q2 2026, buying an estimated $349 and bringing the position to 5,216 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #1547.

AssetMark Inc first reported a position in DNLI in Q3 2022 and has held it in 16 quarters since. 63 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • AssetMark Inc held 5,216 shares of Denali Therapeutics worth $134K as of Q2 2026.
  • AssetMark Inc bought 17 Denali Therapeutics shares in Q2 2026, an estimated $349.
  • Denali Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1547 holding.
  • AssetMark Inc first reported a position in Denali Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 63 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.